Ascendis Pharma Statistics
Total Valuation
Ascendis Pharma has a market cap or net worth of $13.88 billion. The enterprise value is $14.47 billion.
Important Dates
The next confirmed earnings date is Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Ascendis Pharma has 61.78 million shares outstanding. The number of shares has increased by 4.69% in one year.
| Current Share Class | 61.78M |
| Shares Outstanding | 61.78M |
| Shares Change (YoY) | +4.69% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | -1.44% |
| Float | 61.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 69.36 |
| PS Ratio | 16.76 |
| Forward PS | 10.10 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 265.69 |
| P/OCF Ratio | 223.94 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 17.12 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 271.32 |
Financial Position
The company has a current ratio of 1.04
| Current Ratio | 1.04 |
| Quick Ratio | 0.72 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | 19.19 |
| Interest Coverage | -1.69 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -6.86% |
| Return on Invested Capital (ROIC) | -11.67% |
| Return on Capital Employed (ROCE) | -58.44% |
| Weighted Average Cost of Capital (WACC) | 6.94% |
| Revenue Per Employee | $711,121 |
| Profits Per Employee | -$225,181 |
| Employee Count | 1,189 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 0.32 |
Taxes
In the past 12 months, Ascendis Pharma has paid $18.06 million in taxes.
| Income Tax | 18.06M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.49 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 942,359 |
Short Selling Information
The latest short interest is 3.65 million, so 7.22% of the outstanding shares have been sold short.
| Short Interest | 3.65M |
| Short Previous Month | 3.70M |
| Short % of Shares Out | 7.22% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.47 |
Income Statement
In the last 12 months, Ascendis Pharma had revenue of $845.52 million and -$267.74 million in losses. Loss per share was -$4.42.
| Revenue | 845.52M |
| Gross Profit | 734.08M |
| Operating Income | -160.00M |
| Pretax Income | -249.68M |
| Net Income | -267.74M |
| EBITDA | -154.30M |
| EBIT | -160.00M |
| Loss Per Share | -$4.42 |
Full Income StatementBalance Sheet
The company has $723.31 million in cash and $1.02 billion in debt, with a net cash position of -$300.28 million or -$4.86 per share.
| Cash & Cash Equivalents | 723.31M |
| Total Debt | 1.02B |
| Net Cash | -300.28M |
| Net Cash Per Share | -$4.86 |
| Equity (Book Value) | -191.17M |
| Book Value Per Share | -3.11 |
| Working Capital | 46.49M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $63.28 million and capital expenditures -$9.96 million, giving a free cash flow of $53.34 million.
| Operating Cash Flow | 63.28M |
| Capital Expenditures | -9.96M |
| Depreciation & Amortization | 5.70M |
| Net Borrowing | -25.79M |
| Free Cash Flow | 53.34M |
| FCF Per Share | $0.86 |
Full Cash Flow StatementMargins
Gross margin is 86.82%, with operating and profit margins of -18.92% and -31.67%.
| Gross Margin | 86.82% |
| Operating Margin | -18.92% |
| Pretax Margin | -29.53% |
| Profit Margin | -31.67% |
| EBITDA Margin | -18.25% |
| EBIT Margin | -18.92% |
| FCF Margin | 6.31% |
Dividends & Yields
Ascendis Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.69% |
| Shareholder Yield | -4.69% |
| Earnings Yield | -1.89% |
| FCF Yield | 0.38% |
Dividend DetailsAnalyst Forecast
The average price target for Ascendis Pharma is $281.50, which is 25.25% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $281.50 |
| Price Target Difference | 25.25% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (5Y) | 23.09% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ascendis Pharma has an Altman Z-Score of -2.66 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.66 |
| Piotroski F-Score | 4 |
